BioCorRx Inc
biocorrx.comBioCorRx Inc (OTC: BICX) is a pharmaceutical and addiction treatment company focused on developing and commercializing products for substance use disorders. Revenue derives from a combination of grant income and product sales, with grant income of $2,435,848 recognized in FY2025 compared to $1,473,276 in FY2024, representing the dominant income source disclosed in the 10-K filed March 31, 2026. In March 2025, subsidiary BioCorRx Pharmaceuticals Inc. acquired Lucemyra, an FDA-approved prescription medication for opioid withdrawal, from US WorldMeds via an asset purchase agreement with a $400,000 upfront purchase price structured as a 50% net sales revenue share. The company also holds a $11,029,977 National Institutes of Health grant awarded March 1, 2024, funding research on BICX104, a sustained-release naltrexone implant targeting methamphetamine use disorder. Two officers and directors together with five non-employee directors controlled approximately 66.50% of outstanding voting equity as of the FY2025 filing. The company carries accumulated deficit and has funded operations substantially through equity issuances and grants.
Products & Services
Lucemyra: FDA-approved prescription medication for opioid withdrawal, acquired from US WorldMeds in March 2025. BICX104: sustained-release naltrexone implant in research stage targeting methamphetamine use disorder, funded by a $11,029,977 NIH NIDA grant awarded March 1, 2024.
Revenue Model
Grant income from NIH/NIDA awards, product net sales from Lucemyra (opioid withdrawal medication acquired March 2025 via asset purchase), and equity raises including common stock and warrant issuances to accredited investors.
Customers & Markets
End markets are addiction treatment, specifically opioid use disorder and methamphetamine use disorder. Grant funding source is the National Institute on Drug Abuse (NIDA), a division of the National Institutes of Health.
Geographic Exposure
United States. No international operations are disclosed in the filing excerpts.
Financial Snapshot
Loading...
